These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 6850582

  • 1. Comparative cytotoxicity of bisantrene, mitoxantrone, ametantrone, dihydroxyanthracenedione, dihydroxyanthracenedione diacetate, and doxorubicin on human cells in vitro.
    Drewinko B, Yang LY, Barlogie B, Trujillo JM.
    Cancer Res; 1983 Jun; 43(6):2648-53. PubMed ID: 6850582
    [Abstract] [Full Text] [Related]

  • 2. Inhibitory effects of anthracenedione antineoplastic agents on hepatic and cardiac lipid peroxidation.
    Kharasch ED, Novak RF.
    J Pharmacol Exp Ther; 1983 Aug; 226(2):500-6. PubMed ID: 6875860
    [Abstract] [Full Text] [Related]

  • 3. Lethal efficacy of doxorubicin on human medullary thyroid carcinoma cells in vitro.
    Yang KP, Samaan NA.
    Anticancer Res; 1988 Aug; 8(2):245-8. PubMed ID: 3364935
    [Abstract] [Full Text] [Related]

  • 4. Comparative molecular pharmacology in leukemic L1210 cells of the anthracene anticancer drugs mitoxantrone and bisantrene.
    Bowden GT, Roberts R, Alberts DS, Peng YM, Garcia D.
    Cancer Res; 1985 Oct; 45(10):4915-20. PubMed ID: 4027978
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the effects of dihydroxyanthraquinone and adriamycin on the survival of cultured Chinese hamster cells.
    Kimler BF, Cheng CC.
    Cancer Res; 1982 Sep; 42(9):3631-6. PubMed ID: 7105035
    [Abstract] [Full Text] [Related]

  • 6. Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system.
    Cowan JD, Von Hoff DD, Clark GM.
    Invest New Drugs; 1983 Sep; 1(2):139-44. PubMed ID: 6678863
    [Abstract] [Full Text] [Related]

  • 7. Quantitation of differential sensitivity of normal marrow myeloid progenitor cells to anthracene derivatives.
    Bron D, Dodion P, Rozencweig M, Delforge A, Mattelaer MA, Kenis Y, Stryckmans P.
    Invest New Drugs; 1986 Sep; 4(1):11-6. PubMed ID: 3700036
    [Abstract] [Full Text] [Related]

  • 8. [Current clinical status of new anticancer drugs].
    Ogawa M.
    Gan No Rinsho; 1983 Aug; 29(10):1049-52. PubMed ID: 6415310
    [Abstract] [Full Text] [Related]

  • 9. Action of dihydroxyanthraquinone on cell cycle progression and survival of a variety of cultured mammalian cells.
    Traganos F, Evenson DP, Staiano-Coico L, Darzynkiewicz Z, Melamed MR.
    Cancer Res; 1980 Mar; 40(3):671-81. PubMed ID: 6162553
    [Abstract] [Full Text] [Related]

  • 10. Lethal and cytokinetic effects of mitomycin C on cultured human colon cancer cells.
    Barlogie B, Drewinko B.
    Cancer Res; 1980 Jun; 40(6):1973-80. PubMed ID: 7371033
    [Abstract] [Full Text] [Related]

  • 11. Effect of temperature on the cytotoxicity of vindesine, amsacrine, and mitoxantrone.
    Herman TS.
    Cancer Treat Rep; 1983 Nov; 67(11):1019-22. PubMed ID: 6688965
    [Abstract] [Full Text] [Related]

  • 12. Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.
    Lathan B, Von Hoff DD, Elslager E.
    Cancer Treat Rep; 1984 May; 68(5):733-8. PubMed ID: 6233003
    [Abstract] [Full Text] [Related]

  • 13. Effects of cis-dichlorodiammineplatinum(II) on human colon carcinoma cells in vitro.
    Bergerat JP, Barlogie B, Drewinko B.
    Cancer Res; 1979 Apr; 39(4):1334-8. PubMed ID: 421217
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation.
    Koceva-Chyła A, Jedrzejczak M, Skierski J, Kania K, Jóźwiak Z.
    Apoptosis; 2005 Dec; 10(6):1497-514. PubMed ID: 16215684
    [Abstract] [Full Text] [Related]

  • 15. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation.
    Stefańska B, Dzieduszycka M, Bontemps-Gracz MM, Borowski E, Martelli S, Supino R, Pratesi G, De Cesare M, Zunino F, Kuśnierczyk H, Radzikowski C.
    J Med Chem; 1999 Sep 09; 42(18):3494-501. PubMed ID: 10479282
    [Abstract] [Full Text] [Related]

  • 16. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.
    Lown JW, Hanstock CC, Bradley RD, Scraba DG.
    Mol Pharmacol; 1984 Jan 09; 25(1):178-84. PubMed ID: 6708933
    [Abstract] [Full Text] [Related]

  • 17. Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures.
    Herman TS, Teicher BA, Varshney A, Khandekar V, Brann T.
    Anticancer Res; 1992 Jan 09; 12(3):827-36. PubMed ID: 1622142
    [Abstract] [Full Text] [Related]

  • 18. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR, Chen SF, Behrens CH, Papp LM, Stafford MM, Sun JH, Behrens DL, Fredericks JR, Polkus ST, Sipple P.
    Cancer Res; 1994 Apr 15; 54(8):2199-206. PubMed ID: 8174127
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein mediates profound resistance to bisantrene.
    Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, Annable T, Arceci RJ, Durr FE, Greenberger LM.
    Oncol Res; 1994 Apr 15; 6(7):291-301. PubMed ID: 7865904
    [Abstract] [Full Text] [Related]

  • 20. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
    Cowan JD, Osborne CK, Neidhart JA, Von Hoff DD, Constanzi JJ, Vaughn CB.
    Invest New Drugs; 1985 Apr 15; 3(2):149-52. PubMed ID: 3894277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.